Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)

Launched by ASTRAZENECA · Dec 17, 2024

Keywords

ClinConnect Summary

The PROGRESS-CKD trial is a research study taking place in Kazakhstan that aims to understand how often chronic kidney disease (CKD) is diagnosed in patients who have high blood pressure (also known as hypertension) and certain markers that may indicate kidney problems. The study will look at the characteristics of these patients and how their treatment changes before and after they are diagnosed with CKD. This research is important because it helps doctors identify and treat kidney issues earlier, potentially improving patient health outcomes.

To be eligible for this study, participants need to be at least 18 years old and have a confirmed diagnosis of high blood pressure. They should also show signs of kidney issues through specific tests done within the past year, but they should not have a previous diagnosis of CKD in their medical records. If someone decides to participate, they will provide consent and take part in regular follow-ups as the researchers collect information on their health. This study is currently recruiting participants of all genders, and it offers a chance to contribute to important medical knowledge that could benefit others with similar health concerns.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years at the time of inclusion;
• • Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort;
• • Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits
• • Laboratory markers of CKD (eGFR \<60 mL/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≥3 and ≤12 months prior to inclusion in the study without a recorded diagnosis of CKD in the primary medical record prior to inclusion;
• • \* any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), urine total protein(protein)/creatinine ratio ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or proteinuria ≥0.15 mg/d.
• • Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study
• Exclusion Criteria:
• • Absence of a signed ICF in patients in the prospective follow-up group
• • Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study
• • An established diagnosis of type 1 or type 2 diabetes mellitus.
• • Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records
• • Diagnosis of AH of secondary genesis